Find Station
 

Researchers Develop Potential Blood Test For CTE

Cleveland Browns Training Camp

Photo: Nick Cammett / Getty Images Sport / Getty Images

Researchers at Boston University have made a significant breakthrough in diagnosing chronic traumatic encephalopathy (CTE) in living patients. Currently, CTE, a degenerative brain disease linked to repeated head injuries, can only be diagnosed posthumously. The new study, published in the Journal of the American Medical Association, suggests that a blood test could identify the disease in living individuals by detecting elevated levels of a protein called endogenously cleaved microtubule-binding region tau (eMTBR-tau).

The research involved analyzing blood samples from 21 former football players, 18 of whom were later confirmed to have CTE. The study found that those with advanced CTE had significantly higher concentrations of eMTBR-tau compared to those with early-stage or no CTE. Michael Alosco, co-director of clinical research at BU’s CTE Center, described the findings as potentially "a game-changer" for diagnosing CTE during life.

The study also noted that five participants had both CTE and Alzheimer’s disease, with the highest levels of eMTBR-tau found in these individuals. This discovery could help differentiate between CTE and Alzheimer’s using blood markers, as reported by NBC Boston.

While the findings are promising, Alosco emphasized the need for further research. "We really need to do more studies to confirm this finding, better understand this finding, and then get this on a path where hopefully we can bring it to patients one day," he said. If validated, the blood test could lead to earlier diagnoses and new treatments for CTE, potentially moving toward FDA approval within five years.

The study's implications are significant, as diagnosing CTE in living patients could facilitate clinical trials for treatments. The Boston Globe highlighted that the research is still in its early stages, and larger studies are necessary to confirm the results.